NasdaqGS:ALNYBiotechs
GSK Stock Jumps As 3 Biotech Names Gain From Its R And D Reset
GSK has just announced a £1.9b cost cutting program alongside fresh investment in UK life sciences, and the market reaction has been quick, with the stock up 6% on the news. When a major pharmaceuticals and biotechnology group reshapes its R&D footprint and focuses on phase 3 trials, it can ripple across the sector. Some companies may see new competitive pressure, while others may benefit from partnership, supply chain or sentiment shifts. This article looks at 3 stocks from our...